Wednesday, Sep 10, 2008

Genentech Announces Vice President Appointment In Research

South San Francisco, Calif. -- September 10, 2008 --

Genentech, Inc. (NYSE: DNA) today announced the appointment of Morgan Sheng, M.D., Ph.D., to Vice President, Neuroscience, effective September 15, 2008. In this newly created position, Sheng will be responsible for directing neurobiology drug discovery efforts at Genentech and will oversee the department of neurobiology. Sheng will report to Marc Tessier-Lavigne, Ph.D., executive vice president, Research Drug Discovery.

"Morgan is widely recognized as a leading neuroscientist internationally," said Tessier-Lavigne. "Given his exceptional accomplishments in this field, I am confident that he will make significant contributions to our drug discovery efforts."

"We are excited that Morgan will be joining the R&D leadership team," said Richard Scheller, Ph.D., executive vice president, Research and Chief Scientific Officer. "Over the past several years we have initiated major projects in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, glaucoma, and amyotrophic lateral sclerosis (Lou Gehrig's disease). We are beginning to expand more broadly into other areas such as psychiatric disorders and pain. Morgan's interest in these areas and experience in the discovery of novel therapeutic targets will make him a superb addition as we expand our programs in neuroscience."

Sheng will be joining Genentech from the Massachusetts Institute of Technology (MIT) where he is Menicon Professor of Neuroscience at the Picower Institute for Learning and Memory and RIKEN-MIT Neuroscience Research Center in the Departments of Brain and Cognitive Science, and Biology. He is a Howard Hughes Medical Institute Investigator and, among many honors, a Fellow of the Royal Society.

Sheng is a member of numerous scientific advisory boards, serves on the editorial boards of several scientific journals, and has published more than 140 scientific papers.

Sheng received a bachelor of arts in physiology from Oxford University (U.K.) and his medical degree from London University. He became a fully licensed physician in the U.K., specializing in internal medicine. Sheng holds a doctorate in molecular genetics from Harvard University. Following his postdoctoral work in neuroscience at the University of California, San Francisco, Sheng served on the faculty at Massachusetts General Hospital and Harvard Medical School before joining MIT.

About Genentech
Founded more than 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes multiple biotechnology products and licenses several additional products to other companies. The company has headquarters in South San Francisco, California and is listed on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit